List of Excipients in Branded Drug DONEPEZIL HYROCHLORIDE

Generic Drugs Containing DONEPEZIL HYROCHLORIDE

Company	Ingredient	NDC	Excipient
Bi‐Coastal Pharma International LLC	donepezil hydrochloride	42582-311	CELLULOSE, MICROCRYSTALLINE
Bi‐Coastal Pharma International LLC	donepezil hydrochloride	42582-311	LACTOSE MONOHYDRATE
Bi‐Coastal Pharma International LLC	donepezil hydrochloride	42582-311	MAGNESIUM STEARATE
Bi‐Coastal Pharma International LLC	donepezil hydrochloride	42582-311	POLYETHYLENE GLYCOL 3350

What are the Most Frequently-Used Excipients in DONEPEZIL HYROCHLORIDE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL 3350

Donepezil Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Donepezil hydrochloride is a mature, genericized acetylcholinesterase inhibitor used for Alzheimer’s disease. The principal commercial opportunity is not basic immediate-release tablets, where competition and price pressure are high. Higher-value opportunities are in orally disintegrating tablets, low-swallowing-burden products, alcohol-free oral liquids, taste-masked formulations, unit-dose packaging, and differentiated products for patients with dysphagia or adherence problems.

Excipient selection must address four practical constraints: low dose uniformity, bitterness, rapid disintegration, and dose flexibility. Patent risk is generally lower for conventional tablets than for specialized formulations, but formulation patents, manufacturing claims, and method-of-use patents can still affect launch timing and market positioning.

What is donepezil hydrochloride and which dosage forms are commercially relevant?

Donepezil hydrochloride is the hydrochloride salt of donepezil, marketed originally by Eisai and Pfizer under the Aricept brand. FDA-approved strengths and dosage forms have included:

Dosage form	Typical strengths	Commercial role
Immediate-release film-coated tablet	5 mg, 10 mg	Standard generic market
Orally disintegrating tablet	5 mg, 10 mg	Dysphagia and adherence positioning
Higher-strength tablet	23 mg	Moderate-to-severe Alzheimer’s disease; lower-volume dosing
Oral liquid or suspension	Product-specific	Dose flexibility and swallowing support

Donepezil is administered once daily. The approved labeling supports initiation at 5 mg daily, escalation to 10 mg after four to six weeks, and use of 23 mg in selected patients with moderate-to-severe disease who have received 10 mg daily for at least three months.[1]

The low dose creates a content-uniformity challenge. A 5 mg tablet contains a small quantity of active pharmaceutical ingredient relative to the total tablet mass. Powder segregation, inadequate blending, and poor API particle-size control can therefore cause batch-level variability.

What excipients are used in donepezil hydrochloride tablets?

Conventional donepezil tablets typically use a combination of diluent, binder, disintegrant, lubricant, and film-coating materials. Brand and generic formulations differ, and each approved product has its own inactive-ingredient profile.

Common excipient functions include:

Excipient class	Typical examples	Function
Diluent	Lactose monohydrate, microcrystalline cellulose	Increases tablet mass and supports compression
Binder	Hydroxypropyl cellulose, povidone	Improves granule and tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Promotes tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces punch and die friction
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose	Creates a protective and cosmetic coating
Plasticizer	Polyethylene glycol	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides	Controls appearance and light protection
Sweetener	Mannitol, sucralose, aspartame	Supports orally disintegrating products
Flavor	Mint, fruit, or other flavor systems	Masks bitterness in liquid and ODT products

The original Aricept tablet labeling identifies inactive ingredients including lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc, titanium dioxide, and polyethylene glycol.[1] Product-specific generic labels should be reviewed separately because substituting lactose, changing disintegrant levels, or adding a colorant can affect regulatory comparability, tolerability, and marketing claims.

How should an excipient strategy address donepezil’s low dose?

The preferred platform for a conventional tablet is direct compression if the API and excipient blend have adequate flow, segregation resistance, and compactability. Roller compaction or wet granulation may be used where direct compression cannot maintain content uniformity or tablet strength.

A practical development sequence is:

1. Characterize API particle-size distribution, bulk density, flow, crystallinity, and electrostatic behavior.
2. Select a high-functionality diluent with consistent particle size.
3. Use geometric dilution or ordered mixing to distribute the low-dose API.
4. Evaluate segregation during hopper transfer, compression, and packaging.
5. Control magnesium stearate addition time because over-lubrication can slow disintegration and reduce tablet strength.
6. Establish blend and tablet content-uniformity controls early in development.

Microcrystalline cellulose is useful for tablet strength and wicking. Lactose can reduce cost and improve compactability, but it may be unsuitable for products positioned for patients with lactose intolerance or for certain dry-blend systems. Mannitol is more attractive for ODT products because it provides a cooling mouthfeel and lower hygroscopicity than some alternative polyols.

A dual-excipient platform using microcrystalline cellulose plus mannitol can support both mechanical strength and rapid disintegration. The final choice depends on target tablet weight, tooling, manufacturing process, and taste-masking requirements.

What excipients are best for donepezil orally disintegrating tablets?

The main ODT requirements are rapid disintegration, acceptable mouthfeel, mechanical durability, and bitterness control. Donepezil has a pronounced bitter taste, making an unprotected ODT unsuitable for many patients.

A commercially viable ODT formulation may use:

• Mannitol as the primary filler and mouthfeel agent.
• Microcrystalline cellulose or a compressible co-processed excipient for structure.
• Crospovidone or croscarmellose sodium for rapid water uptake.
• Low-level magnesium stearate or sodium stearyl fumarate for lubrication.
• Sucralose, aspartame, or another sweetener for taste correction.
• A flavor system compatible with the API and packaging environment.
• A polymeric taste-masking coating or ion-exchange complex where simple sweetening is inadequate.

Direct-compression ODTs generally offer a lower manufacturing burden than lyophilized wafer products. They also have better mechanical robustness during distribution. Lyophilized or porous wafer technologies can disintegrate rapidly but may require higher-cost manufacturing, specialized packaging, and stronger moisture protection.

The most defensible ODT claims should focus on disintegration, handling, dose administration, and taste. Claims implying improved clinical efficacy or superior cognitive outcomes would require clinical substantiation and may create unnecessary regulatory exposure.

What formulation patents protect donepezil hydrochloride products?

The original donepezil composition and early pharmaceutical patents are old. Donepezil hydrochloride entered the market in the 1990s, and core product exclusivity has expired in the United States. The commercial patent question now centers on later dosage forms, manufacturing processes, solid-state properties, and delivery systems.

Potentially relevant claim categories include:

Claim category	Commercial relevance
Orally disintegrating tablets	Protects rapid-dissolving dosage platforms and excipient combinations
Taste-masked particles	May protect coated API, polymer matrices, or multiparticulates
Oral liquids	May cover pH control, preservatives, suspensions, and dose stability
Modified-release systems	Could limit once-daily or reduced-fluctuation products
High-strength 23 mg tablets	May involve manufacturing and dosage-form claims
Polymorphs or particle engineering	Can affect API sourcing and process design
Manufacturing methods	May restrict granulation, coating, compression, or blending steps
Combination products	May involve donepezil with memantine or other agents

A formulation patent is not automatically a barrier to a conventional generic launch. The relevant question is whether the proposed product practices a valid, enforceable claim. Developers should screen patent families in the United States, Europe, Japan, and other target markets, then compare the claims against the actual excipient system, process, and dosage form.

What is the Orange Book status of donepezil hydrochloride?

The FDA Orange Book lists approved donepezil hydrochloride products and any relevant patent or exclusivity information associated with approved applications.[2] Core immediate-release donepezil tablets are generally treated as mature generic products with multiple approved ANDAs.

The regulatory pathway is typically an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A generic product must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. An ANDA applicant must also address listed patents and exclusivities using the applicable certification under 21 U.S.C. § 355(j)(2)(A)(vii).

For conventional immediate-release tablets, the principal regulatory issues are:

• Same active ingredient and dosage form.
• Equivalent strength.
• Pharmaceutical equivalence.
• Bioequivalence.
• Acceptable inactive ingredients.
• Adequate stability and dissolution.
• Compliance with current good manufacturing practice.

ODTs and oral liquids can require additional attention to dosage-form performance, in-use stability, dose delivery, microbial control, and excipient safety. The Orange Book should be checked at the time of filing because listings and application status can change.

When does donepezil hydrochloride lose exclusivity?

Donepezil’s foundational U.S. exclusivity has already expired. The original Aricept tablets entered U.S. approval in 1996, and generic competition subsequently developed across the 5 mg and 10 mg strengths.[1,3]

The commercial timetable now depends on the specific product:

Product type	Exclusivity position	Generic-entry implication
5 mg immediate-release tablet	Mature generic market	High price competition
10 mg immediate-release tablet	Mature generic market	High price competition
5 mg and 10 mg ODT	Generic availability exists, but formulation differentiation remains possible	Moderate opportunity in selected channels
23 mg tablet	Mature product with more limited demand than 5 mg and 10 mg	Potentially less crowded, but smaller market
Oral liquid	Product-specific availability	Opportunity if stability and taste are solved
Novel modified-release product	Depends on new patents and FDA approval	Potentially protected, but higher development risk

A developer should not rely on the age of the active ingredient alone. A new formulation can generate its own patent term, regulatory exclusivity, or market differentiation, but the claims must be drafted around a real technical advantage.

Are there Paragraph IV challenges or biosimilar risks for donepezil?

Paragraph IV risk is most relevant to listed patents associated with an approved reference product. Because the core donepezil tablet market is mature, the main current risk is product-specific rather than molecule-wide. An ANDA applicant challenging a remaining listed patent may file a Paragraph IV certification and trigger patent litigation under the Hatch-Waxman framework.[4]

Biosimilar risk does not apply. Donepezil hydrochloride is a small-molecule drug, not a biologic. Competitive entry occurs through ANDAs and, for certain non-equivalent products, potentially through 505(b)(2) applications.

A 505(b)(2) strategy may be relevant for:

• A novel oral liquid.
• A modified-release formulation.
• A combination product.
• A new dosage form with clinical or pharmacokinetic differentiation.
• A product using a new route of administration.

The 505(b)(2) route can support new intellectual property but generally requires more development work than a standard ANDA.

Which excipient-driven commercial opportunities are most attractive?

The strongest opportunities are linked to administration problems rather than the active ingredient itself.

Dysphagia-focused products

Alzheimer’s patients often have difficulty swallowing tablets. An ODT, oral liquid, or soft, rapidly dispersing product can address this problem. The commercial value depends on whether the product is easier to administer without creating dose loss, unacceptable taste, or caregiver burden.

Taste-masked oral liquids

A stable, preservative-controlled, alcohol-free oral liquid could support patients who cannot swallow tablets and caregivers who need flexible dosing. Key formulation issues include:

• API solubility at the target concentration.
• pH control.
• Chemical stability.
• Preservative effectiveness.
• Dose uniformity after storage.
• Compatibility with oral syringes and dosing cups.
• Bitterness and aftertaste.
• Container closure and adsorption.

A suspension may provide better chemical stability than a solution, but it requires robust redispersibility and shake-use instructions.

Low-cost ODTs

A direct-compression ODT using mannitol, a superdisintegrant, a flavor system, and a taste-masking approach can target retail, institutional, and specialty-pharmacy channels. The product should maintain adequate hardness for packaging while disintegrating quickly in the mouth.

Unit-dose and adherence packaging

Calendar blister packs, caregiver-oriented unit-dose systems, and moisture-protective packaging can create commercial value without changing the core formulation. Packaging claims must remain distinct from drug efficacy claims.

Combination products

Donepezil and memantine are both used in Alzheimer’s disease management. A fixed-dose combination may reduce pill burden, but it is a more complex regulatory and clinical project. The developer must address dose titration, patient selection, compatibility, and whether the combination improves adherence or clinical management.

How strong is the donepezil hydrochloride patent estate?

The estate is weak for standard immediate-release tablets and stronger for genuinely differentiated delivery systems. A practical assessment is:

Area	Patent strength	Commercial assessment
Basic donepezil tablet	Low	Commodity generic market
Conventional film coating	Low	Limited differentiation
ODT architecture	Moderate	Depends on claim scope and prior art
Taste masking	Moderate	Can support proprietary platform claims
Oral liquid	Moderate	Stability and preservation claims may be valuable
Modified release	Potentially high	Requires technical proof and market demand
Manufacturing process	Variable	Useful if difficult to design around
Packaging and adherence system	Low to moderate	Usually supports branding more than exclusivity

Patent strength depends on claim breadth, written-description support, enablement, prosecution history, prior art, and freedom-to-operate analysis. A narrow excipient claim is unlikely to block all competitive products. A broader formulation claim supported by multiple excipient ranges, processing routes, and performance data has greater defensive value.

What generic launch scenarios exist for donepezil hydrochloride?

Scenario 1: Standard ANDA tablet

This is the lowest-risk route but also the least attractive commercially. The product competes primarily on acquisition cost, supply reliability, quality history, and wholesaler access.

Scenario 2: ODT with taste masking

This route offers a stronger value proposition for dysphagia and caregiver administration. It requires more development work but may support better channel differentiation.

Scenario 3: 505(b)(2) oral liquid

An oral liquid can address an underserved administration need. The principal risks are stability, taste, microbial control, dosing accuracy, and the cost of clinical or bridging studies.

Scenario 4: 23 mg product

The 23 mg strength may face less intense competition than 5 mg and 10 mg tablets, but the patient population and prescription volume are smaller. Manufacturing and dose-titration considerations also limit the opportunity.

Scenario 5: Fixed-dose combination

A combination product can reduce pill burden but requires substantial clinical, regulatory, and commercial validation. It is a higher-investment strategy than an ANDA.

How does donepezil compare with competing Alzheimer’s drugs?

Donepezil competes with other symptomatic therapies, including rivastigmine, galantamine, and memantine. It also competes indirectly with newer disease-modifying therapies such as lecanemab, although the treatment objectives and patient populations differ.

Drug	Product type	Excipient opportunity
Donepezil	Small-molecule acetylcholinesterase inhibitor	ODT, liquid, taste masking, adherence packaging
Rivastigmine	Capsule, oral solution, transdermal patch	Patch and low-dose delivery technologies
Galantamine	Tablet, capsule, oral solution	Modified release and liquid dosing
Memantine	Tablet, capsule, oral solution	Combination and liquid formulations
Lecanemab	Monoclonal antibody infusion	Biologic formulation and infusion logistics, not generic excipient substitution

Donepezil has the broadest opportunity for low-cost oral reformulation because its core product is old, widely prescribed, and available through generic channels. Rivastigmine’s transdermal system creates a different competitive benchmark, particularly for patients with swallowing difficulty.

What manufacturing and IP barriers affect commercial entry?

The largest technical barriers are not API novelty. They are reproducible low-dose blending, bitterness control, ODT mechanical strength, liquid stability, and reliable supply of pharmaceutical-grade excipients.

Manufacturers should prioritize:

• API-excipient compatibility studies.
• Blend uniformity under scale-up conditions.
• Segregation testing after transfer and vibration.
• Dissolution comparison across manufacturing sites.
• Moisture and temperature stability.
• Extractables and leachables for liquid products.
• Preservative effectiveness for multidose liquids.
• Packaging integrity for moisture-sensitive ODTs.
• Supplier qualification for mannitol, superdisintegrants, flavors, and taste-masking polymers.

Geographic patent exposure is likely to be more important for specialized formulations than for ordinary tablets. The United States, European Union, Japan, China, Canada, and Australia should be reviewed independently because patent scope, Orange Book practice, regulatory pathways, and generic litigation rules differ.

Key Takeaways

• Donepezil hydrochloride is a mature small-molecule product with expired core exclusivity and substantial generic competition.
• Conventional 5 mg and 10 mg tablets are low-margin opportunities unless supported by supply, cost, or channel advantages.
• ODTs, taste-masked liquids, and caregiver-oriented packaging offer the clearest excipient-led opportunities.
• Microcrystalline cellulose, mannitol, superdisintegrants, controlled lubrication, and taste-masking systems are central formulation tools.
• Low-dose content uniformity and bitterness are the main technical formulation risks.
• Biosimilar competition is irrelevant because donepezil is not a biologic.
• Patent risk is concentrated in later formulation, manufacturing, modified-release, and combination-product claims.
• A standard ANDA is the lowest-risk route; a 505(b)(2) liquid or modified-release product offers greater differentiation but requires more evidence.
• Current FDA Orange Book listings and product-specific patent records should control any launch or Paragraph IV analysis.

FAQs

Is donepezil hydrochloride compatible with lactose?

Lactose is used in some donepezil tablet formulations, including the original tablet formulation. Compatibility must still be confirmed through stability, impurity, and process studies for the proposed product.

What is the best filler for a donepezil ODT?

Mannitol is often attractive because it supports mouthfeel and rapid dispersion. Microcrystalline cellulose or a co-processed excipient may be added to improve compactability and tablet strength.

Can donepezil hydrochloride be formulated as an oral solution?

It can be evaluated as an oral solution, but commercial development depends on solubility, pH stability, taste masking, preservative control, container compatibility, and dose uniformity. A suspension may be preferable if solution stability is inadequate.

Does an ODT donepezil product require a new patent?

No. An ODT can be developed as a generic product if it meets the applicable regulatory requirements and does not infringe enforceable listed or non-listed patent claims. A new patent may be available only if the formulation or process has patentable technical features.

Is 23 mg donepezil commercially attractive?

The 23 mg strength offers a differentiated dose and may face less competition than the 5 mg and 10 mg strengths, but its addressable market is smaller and dose-escalation requirements narrow the patient population.

References

1. U.S. Food and Drug Administration. (2010). Aricept (donepezil hydrochloride) prescribing information. Eisai Inc.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (1996). NDA 020690: Aricept approval history and labeling.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).